US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Militia Long/Short Equity ETF

29.50

+0.39001.34%

Post-market: 29.500.00000.00%16:00 EDT

Volume:23.63K

Turnover:696.09K

Market Cap:- -

PE:- -

High:29.71

Open:29.71

Low:29.30

Close:29.11

Loading ...

Overview Company News Filings

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

Merck KGaA (MKGAF) Files for Global Approval of Pimicotinib After Positive Phase III TGCT Results

AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio

Press Release: Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update

Press Release: ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

Press Release: SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Press Release: Immatics Announces First Quarter 2025 Financial Results and Business Update

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched Subgroups

Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development

Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST

Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ORR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":29.5,"timestamp":1751054400000,"preClose":29.11,"halted":0,"volume":23629,"hourTrading":{"tag":"盘后","latestPrice":29.5,"preClose":29.5,"latestTime":"16:00 EDT","volume":15,"amount":442.5,"timestamp":1751054402295},"delay":0,"floatShares":2870000,"shares":0,"eps":0,"marketStatus":"Market Closed","change":0.39,"latestTime":"06-27 16:00:00 EDT","open":29.71,"high":29.71,"low":29.3,"amount":696091.5463,"amplitude":0.014085,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751270400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":29.11,"sharesOutstanding":2870000,"nav":29.02,"aum":83287400,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":29.22,"preClose":29.09,"latestTime":"09:28 EDT","volume":60,"amount":1753.1999999999998,"timestamp":1751030924719},"postHourTrading":{"tag":"盘后","latestPrice":29.5,"preClose":29.5,"latestTime":"16:00 EDT","volume":15,"amount":442.5,"timestamp":1751054402295},"volumeRatio":1.0280451084091622},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":2870000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.0280451084091622,"shares":0,"dividePrice":0,"high":29.71,"amplitude":0.014085,"preClose":29.11,"low":29.3,"week52Low":25.63,"pbRate":"--","week52High":29.71,"institutionHeld":0,"latestPrice":29.5,"eps":0,"divideRate":0,"volume":23629,"delay":0,"ttmEps":0,"open":29.71,"prevYearClose":25.88,"prevWeekClose":28.65,"prevMonthClose":28.1031,"prevQuarterClose":27.84,"fiveDayClose":28.65,"twentyDayClose":28.2522,"sixtyDayClose":27.92},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540737112","title":"Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2540737112","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540737112?lang=en_us&edition=fundamental","pubTime":"2025-06-02 01:12","pubTimestamp":1748797920,"startTime":"0","endTime":"0","summary":"Median DOR of 21.7 months with 80% of responders achieving a deep response . Depth and durability translating to prolonged OS with median OS of 21.3 months and 2-year OS of 46% in HPV-negative HNSCC. Conference call and webcast today at 3:00 p.m. CT / 4:00 p.m. ET. In the Phase 1/1b trial, ficerafusp alfa in combination with pembrolizumab resulted in deep and durable anti-tumor activity with improved overall survival  compared to historical benchmarks in patients with 1L R/M human papillomavirus-negative HNSCC with a PD-L1 combined positive score  of ≥1 and with at least 24 months of follow-up.In the efficacy evaluable human papillomavirus-negative population :. Median OS of 21.3 months; 2-year OS rate of 46%.54%  confirmed objective response rate ; 64%  ORR, including an additional three unconfirmed responses.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bicara-therapeutics-demonstrates-deep-durable-171200341.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BCAX","BK4097","OS","CPS","ORR","BK4124"],"gpt_icon":0},{"id":"2539830210","title":"Merck KGaA (MKGAF) Files for Global Approval of Pimicotinib After Positive Phase III TGCT Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2539830210","media":"Insider Monkey","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539830210?lang=en_us&edition=fundamental","pubTime":"2025-05-30 03:48","pubTimestamp":1748548115,"startTime":"0","endTime":"0","summary":"Merck KGaA  is seeking worldwide regulatory approval for its CSF-1R inhibitor pimicotinib following robust Phase III results in tenosynovial giant cell tumour . The MANEUVER trial, conducted with Abbisko Therapeutics, showed a 61.9% overall response rate  by tumour volume score  after 25 weeks, far surpassing placebo . This efficacy outperformed Daiichi Sankyo’s Turalio  and was just behind Ono Pharmaceutical’s Romvimza , which received FDA approval in February 2025.Quality of life improvements were notable, with significant gains in range of movement, stiffness, and pain reduction. Importantly, pimicotinib demonstrated a favorable safety profile: while all patients experienced some adverse events, only 4.8% were serious, and there were no signs of liver toxicity, a key differentiator from other therapies.TGCT, a rare non-cancerous joint tumour, often recurs after surgery, making effective drug options crucial. Merck KGaA , having secured global rights from Abbisko in March 2025, has f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/merck-co-inc-mrk-files-042935298.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999014559.SGD","LU2461242641.AUD","LU1066051498.USD","IE00BLSP4452.SGD","LU2361044949.HKD","LU2468319806.SGD","LU1291159041.SGD","IE0009355771.USD","ORR","LU0965509010.AUD","IE00BBT3K403.USD","LU0070302665.USD","LU1430594728.SGD","LU0208291251.USD","LU1061106388.HKD","LU1989771016.USD","LU0266013472.USD","MKGAF","LU1917777945.USD","LU0861579265.USD","LU2324357040.USD","LU1941712264.USD","LU1974910355.USD","MRK","BK4007","LU2361044865.SGD","LU0106261372.USD","LU1585245621.USD","LU2089984988.USD","IE00BLSP4239.USD","LU1116320737.USD","SG9999002224.SGD","LU1934455277.USD","LU1066051225.USD","LU0006306889.USD","BK4588","LU0985320562.USD","IE000M9KFDE8.USD","III","SG9999013999.USD","SG9999001440.SGD","BK4559","IE0002141913.USD","IE00B1BXHZ80.USD","LU0965509283.SGD","LU0265550946.USD","LU0965508806.USD","LU1069347547.HKD","LU1037948897.HKD","IE00B4R5TH58.HKD"],"gpt_icon":0},{"id":"2539296289","title":"AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2539296289","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539296289?lang=en_us&edition=fundamental","pubTime":"2025-05-27 21:00","pubTimestamp":1748350800,"startTime":"0","endTime":"0","summary":"-  Key oral presentations highlight new data from AbbVie's novel investigational antibody-drug conjugates  including telisotuzumab adizutecan  in advanced non-small cell lung cancer , ABBV-706 in high-grade neuroendocrine neoplasms  and pivekimab sunirine  in blastic plasmacytoid dendritic cell neoplasm .NORTH CHICAGO, Ill., May 27, 2025 /PRNewswire/ -- AbbVie  today announced that key data from its broad oncology portfolio will be showcased across multiple oral presentations and posters at the upcoming American Society of Clinical Oncology  Annual Meeting . These new data highlight significant progress in AbbVie's robust oncology pipeline, across a range of difficult-to-treat solid tumors and blood cancers.\"The data we're presenting at this year's ASCO reflect the breadth and depth of our oncology pipeline and our unwavering commitment to research that could transform outcomes for patients facing cancer,\" said Roopal Thakkar, M.D., executive vice president, research and development an","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/abbvie-features-data-across-difficult-130000579.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abbvie-features-data-across-difficult-130000579.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1989772923.USD","IE0002141913.USD","LU2089984988.USD","ABBV","LU1934455194.USD","SG9999001440.SGD","LU2468319806.SGD","IE0002270589.USD","CCR","CR","LU2087621335.USD","LU1496350502.SGD","LU1430594728.SGD","MT","LU2129689514.USD","LU1162221912.USD","BK4581","IE00B3PB1722.GBP","ORR","LU0795875086.SGD","LU0943347566.SGD","LU2133065610.SGD","IE00BJT1NW94.SGD","LU1093756325.SGD","LU0114720955.EUR","LU0234570918.USD","LU2237443895.HKD","LU1037948541.HKD","ADC","BK4213","IE00B19Z3581.USD","LU0912757837.SGD","LU0882574055.USD","BK4585","SG9999015945.SGD","CRC","LU0965509101.SGD","LU1934455863.HKD","IE00B19Z3B42.SGD","LU0545039389.USD","LU1037948897.HKD","LU1551013425.SGD","LU0122379950.USD","LU2112291526.USD","LU0029864427.USD","LU1267930490.SGD","IE0004445239.USD","LU1989771016.USD","BK4566"],"gpt_icon":0},{"id":"2536373266","title":"Press Release: Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2536373266","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536373266?lang=en_us&edition=fundamental","pubTime":"2025-05-20 04:01","pubTimestamp":1747684860,"startTime":"0","endTime":"0","summary":"- Interim Jan-2025 results from three trials of Alpha DaRT in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium and R&D Update Day, showing >90% disease control rate, impressive overall survival in sub-group analyses, and positive safety profile -. - 75% systemic objective response rate  and 37.5% complete response rate meaningfully higher thus far than historical Keytruda monotherapy data in Jan-2025 interim read out of a combination trial of Alpha DaRT and Keytruda in head and neck squamous cell carcinoma  -. - FDA approval of Investigational Device Exemption  and IDE supplement to conduct a U.S. pilot study of Alpha DaRT together with first-line chemotherapy in patients with newly diagnosed locally advanced or metastatic pancreatic cancer -. - FDA approval of IDE to conduct a U.S. pilot study of Alpha DaRT in patients with recurrent glioblastoma multiforme , a highly aggressive brain cancer -","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDE","DRTS","BK4232","R","BK4082","ORR","BK4022"],"gpt_icon":0},{"id":"2535025235","title":"Press Release: ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535025235","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535025235?lang=en_us&edition=fundamental","pubTime":"2025-05-14 20:00","pubTimestamp":1747224000,"startTime":"0","endTime":"0","summary":"LOTIS-7 abstract accepted for presentation at the European Hematology Association 2025 Congress  and the 18 International Conference on Malignant Lymphoma ; ZYNLONTA plus glofitamab demonstrated ORR of 95.5% and CR of 90.9% with encouraging safety and tolerability. Cash runway expected to fund multiple catalysts into the second half of 2026. LAUSANNE, Switzerland, May 14, 2025 /PRNewswire/ -- ADC Therapeutics SA , a commercial-stage global leader and pioneer in the field of antibody drug conjugates , today reported financial results for the first quarter ended March 31, 2025, and provided recent operational updates.\"We are encouraged by the promising LOTIS-7 abstract data, which we believe demonstrate the potential for ZYNLONTA plus glofitamab to be a best-in-class combination in a dynamic market,\" said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. \"Coupled with the progress of our LOTIS-5 confirmatory trial, we are confident in our path forward and the potential of ZYNLON","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","CR","BK4007","BK4211","PFS","BK4505","BK4195","BK4022","BK4161","BK4232","PBD","BK4080","BK4539","ADCT","BK4139","ORR","ADC","R","BK4231"],"gpt_icon":0},{"id":"2535084331","title":"Press Release: SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535084331","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535084331?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:05","pubTimestamp":1747166700,"startTime":"0","endTime":"0","summary":"-- SLS009 Shows Promising Efficacy in Pediatric Acute Lymphoblastic Leukemia  Xenograft Models --. -- Final Analysis of Pivotal Phase 3 REGAL Trial of Galinpepimut-S  in AML Anticipated in 2025 --. -- $28.4 million in Cash and Cash Equivalents as of March 31, 2025; Additional $4.0 million Proceeds received in April 2025 through Warrant Exercises --. NEW YORK, May 13, 2025  -- SELLAS Life Sciences Group, Inc.  , a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update.Presented Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference: Preclinical data suggest tha","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","BK4139","LU1699723380.USD","LU1571399168.USD","BK4232","BK4588","PDX","BK4022","SLS","ORR","CR","LU2355687059.USD","BK4107","PR","LU0985320562.USD","R","OS","BK4585","BK4213","ALL","BK4161","BK4533"],"gpt_icon":0},{"id":"2535726182","title":"Press Release: Immatics Announces First Quarter 2025 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535726182","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535726182?lang=en_us&edition=fundamental","pubTime":"2025-05-13 19:00","pubTimestamp":1747134000,"startTime":"0","endTime":"0","summary":"-- IMA203 PRAME Cell Therapy: Randomized-controlled Phase 3 trial, SUPRAME,in previously treated advanced melanoma ongoing and expected to complete. data in metastatic melanoma with substantially longer follow-up and. additional uveal melanoma patients to be presented in an oral. -- IMA203CD8 PRAME Cell Therapy : Phase 1a clinical trial in solid. -- IMA402 PRAME Bispecific: Phase 1a clinical trial in solid tumors ongoing. -- Combination of IMA203 PRAME cell therapy and Moderna's PRAME adaptive. -- IMA401 MAGEA4/8 Bispecific: Phase 1a clinical trial, including a. IMA203 is Immatics' lead PRAME cell therapy, currently being evaluated in a Phase 3 trial  in patients with previously treated advanced melanoma. IMA203 has the potent","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","BK4195","BK4211","PFS","BK4097","IMTX","BK4139","OS"],"gpt_icon":0},{"id":"2532858279","title":"Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2532858279","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532858279?lang=en_us&edition=fundamental","pubTime":"2025-05-02 08:24","pubTimestamp":1746145440,"startTime":"0","endTime":"0","summary":"Decision to submit based on a positive overall response rate  , one of the dual primary endpoints in the Phase 3 EPCORE FL-1 trial. The decision to submit the sBLA is supported by positive topline results from the Phase 3 EPCORE FL-1 trial evaluating epcoritamab plus R2 versus R2 alone in adult patients with R/R FL. Based on an interim analysis conducted by an Independent Data Monitoring Committee  review, the study met one of its dual primary endpoints of ORR . The safety profile of epcoritamab plus R2 in adult patients with R/R FL was consistent with the known safety profiles of the individual regimens  and as presented in the U.S. prescribing information for epcoritamab. No new safety signals were observed. The full results will be submitted later this year for presentation at an upcoming medical congress and discussed with global regulatory authorities.About Follicular Lymphoma FL is typically an indolent  form of non-Hodgkin's lymphoma  that arises from B-lymphocytes and is the se","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/genmab-submit-supplemental-biologics-license-002400918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GMAB","FL","LU2065731478.USD","ORR","BK4585","IE00B7SZL793.SGD","IE00B19Z4B17.USD","BK4139","BK4006","CRS","IE0031619046.USD","IE00B66KJ199.SGD","BK4588","BK4094"],"gpt_icon":0},{"id":"2531203126","title":"CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2531203126","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531203126?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:15","pubTimestamp":1746015300,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., April 30, 2025  -- CERo Therapeutics Holdings, Inc.,   an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that TriStar Centennial Medical Center, through Sarah Cannon Research Institute , in Nashville, Tennessee, is a clinical trial site for the Company’s Phase 1 clinical of CER-1236. Collaborating with SCRI to advance cancer research, TriStar Centennial offers innovative clinical research trials for various disease indications. The trial is focused on patients with acute myeloid leukemia , and patient enrollment is underway, with expected dosing of the first patient during the first half of 2025.CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cero-therapeutics-holdings-inc-announces-121500799.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CEROW","CERO","BK4181","BK4218","CR","BK4139","ORR","PK","BK4161"],"gpt_icon":0},{"id":"2531392850","title":"Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched Subgroups","url":"https://stock-news.laohu8.com/highlight/detail?id=2531392850","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531392850?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:00","pubTimestamp":1746010800,"startTime":"0","endTime":"0","summary":"Statistically significant efficacy in biomarker subgroup analyses was observed:. 78% reduction in risk of death and 81% reduction in risk of progression or death in defined pretreatment ranges of serum or tumor CEACAM1 subgroup. 61% reduction is risk of death and 72% reduction in risk of progression or death in defined pretreatment ranges of serum CEACAM1 or myeloperoxidase  subgroup. 90% reduction is risk of death and 81% reduction in risk of progression or death in high tumor CEACAM1 and low PD-L1 combined positive score  subgroup. The biomarkers identified in the Phase 2 study are planned to be used for patient selection in the next Phase 2b study. Prolongation of 2.4 months in OS HR=0.81  and prolongation of 1.9 months in PFS HR=0.75  vs. control arm","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/purple-biotech-reports-final-data-110000531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","IE00B12V2V27.USD","BK4211","BK4124","BK4195","BK4116","BK4563","BK4548","BK4552","BK4526","NET","SG9999011746.SGD","LU2039709279.SGD","BK4531","BK4007","PFS","BK4535","LU0359201612.USD","IE00BYTNYN87.SGD","IE00BYQNZ168.SGD","BK4097","BK4554","BK4571","01698","BK4108","BK4607","CPS","OS","LU1023057109.AUD","LU2286300806.USD","PPBT","LU0359202008.SGD","BK4560","BK4588","BK4613","BK4509","BK4565","ORR","TME"],"gpt_icon":0},{"id":"2531759499","title":"Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2531759499","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531759499?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:00","pubTimestamp":1745935200,"startTime":"0","endTime":"0","summary":"An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer  who received AFM24 at 480 mg weekly demonstrates that higher drug exposure  leads to improved objective response rate  and longer progression free survival   without a negative impact on safety. These findings will be incorporated in future AFM24 trials to further improve efficacy outcomes of patients treated with AFM24. MANNHEIM, Germany, April 29, 2025  -- Affimed N.V. , a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented findings on an exposure-outcome analysis of its innate cell engager  AFM24, in patients with advanced or metastatic non-small cell lung cancer  in a poster session at the 2025 Annual Meeting of the American Association for Cancer Research .The analysis is based on post-hoc exposure-response data from 72 NSCLC patients treated with 480 mg of AFM24 monotherapy or a combination of AFM24 with atezolizumab. F","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/affimed-shows-higher-exposure-afm24-140000007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4181","BK4097","BK4195","PFS","BK4218","PK","AFMD","BK4211","ORR","OS","BK4139"],"gpt_icon":0},{"id":"2531267717","title":"Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531267717","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531267717?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:01","pubTimestamp":1745870460,"startTime":"0","endTime":"0","summary":"BOSTON, April 28, 2025  -- Bicara Therapeutics Inc. , a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced multiple presentations related to ficerafusp alfa at the American Association for Cancer Research  Annual Meeting 2025. Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets: an epidermal growth factor receptor  directed monoclonal antibody with a domain that binds to human transforming growth factor beta  and is being evaluated across multiple solid tumor types.Dual blockade of EGFR and TGF-β with ficerafusp alfa has the potential to overcome resistance mechanisms in 1L R/M HNSCC in combination with pembrolizumab. Spatial transcriptomics revealed downregulation of epithelial-mesenchymal transition and hypoxia pathways in human papillomavirus-negative tumors with ficerafusp alfa and pembrolizumab, supporting the potential role of TGF-β","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bicara-therapeutics-highlights-broad-potential-200100551.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ORR","BCAX","BK4139"],"gpt_icon":0},{"id":"2531558002","title":"Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531558002","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531558002?lang=en_us&edition=fundamental","pubTime":"2025-04-29 01:38","pubTimestamp":1745861880,"startTime":"0","endTime":"0","summary":"90% of patients achieved high grade disease-free status at any time point with NDV-01, demonstrating strong proof-of-concept for sustained-release “GEM/DOCE” formulation*. NDV-01 showed promising clinical activity in BCG-nave and BCG-unresponsive patients, with favorable overall tolerability. Data to be reviewed at Investor Event on April 28, 2025 at 4:30 PM ET. CORAL GABLES, Fla., April 28, 2025  -- Relmada Therapeutics, Inc. , a clinical-stage biotechnology company, today announced that positive initial data from the Phase 2 study of NDV-01 showed that 90% of patients achieved high-grade disease-free status at any time point following treatment, demonstrating strong clinical activity and supporting further development of NDV-01 for the treatment of non-muscle invasive bladder cancer . The data were presented today at the American Urology Association 2025  Annual Meeting with a data cutoff date of April 20, 2025. To register for the virtual Investor Event, click here.Overall: The trea","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/relmada-therapeutics-presents-positive-initial-173800225.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ORR","LENZ","CR","RLMD","BK4161","BK4007"],"gpt_icon":0},{"id":"2530054444","title":"Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC","url":"https://stock-news.laohu8.com/highlight/detail?id=2530054444","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530054444?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:00","pubTimestamp":1745841600,"startTime":"0","endTime":"0","summary":"Phase 2 registration-intent trial enrolling Part 2a dose confirmation arms. Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback. SAN DIEGO, April 28, 2025  -- Zentalis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that the first patient has been dosed in Part 2 of the Phase 2 DENALI clinical trial  of azenosertib in patients with Cyclin E1+ platinum-resistant ovarian cancer .As previously disclosed, the Company aligned with the U.S. Food and Drug Administration  on the design of DENALI Part 2, which allows for seamless enrollment in the two parts of the trial:. Part 2b is designed to enroll approximately 70 additional patients at the selected dose, which will be informed by the Part 2a results, subject to FDA feedback.Azenosertib is a n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zentalis-pharmaceuticals-announces-first-patient-120000488.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PROC","ORR","BK4007","ZNTL","BK4139"],"gpt_icon":0},{"id":"2530147098","title":"BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2530147098","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530147098?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:30","pubTimestamp":1745839800,"startTime":"0","endTime":"0","summary":"Overall survival and clinical benefit in Phase 2 continue to outperform historical benchmarks, including very heavily pretreated patients. Clinical benefit observed in 83% of evaluable patient sub-group treated with the phase 3 formulation. Improved new Bria-OTS+ platform provides powerful innate and adaptive immune system activation. Title:Survival outcomes in a randomized phase 2 ofBria-IMT: An allogeneic whole cell cancer vaccineSession Title:Phase II and Phase III Clinical TrialsSession Start:4/28/2025 2:00 PM – 5:00 PM CSTLocation:Poster Section 50Poster Board Number:18Abstract Presentation Number:CT100. “We are thrilled to share impressive survival and clinical efficacy data at AACR on the advantages of using Bria-IMT plus checkpoint inhibitor in heavily treated patients who have failed multiple prior treatments, including ADCs and CPIs,” stated lead author, Saranya Chumsri, MD, Principal Investigator and Professor of Oncology, Mayo Clinic. “Treatment options have been limited fo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-presents-benchmark-beating-survival-113000613.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","BCTXW","BCTXZ","BK4139","ORR","BCTX","OS"],"gpt_icon":0},{"id":"2530040513","title":"Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST","url":"https://stock-news.laohu8.com/highlight/detail?id=2530040513","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530040513?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:30","pubTimestamp":1745839800,"startTime":"0","endTime":"0","summary":"– Phase 1 dose-escalation study to evaluate ziftomenib in combination with imatinib in patients with advanced GIST after imatinib failure –。– Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive and imatinib-resistant GIST preclinical models –。SAN DIEGO, April 28, 2025  -- Kura Oncology, Inc. , a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the first patients have been dosed in KOMET-015, a Phase 1 clinical trial of ziftomenib, the Company’s potent and selective, oral investigational menin inhibitor, in patients with advanced gastrointestinal stromal tumors  after imatinib failure.“Until now, most approaches to treating gastrointestinal stromal tumors rely on targeted KIT inhibition via tyrosine kinase inhibitors such as imatinib, however most patients eventually progress due to acquired secondary KIT mutations highlighting the need","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kura-oncology-announces-first-patients-113000397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0031619046.USD","BK4097","IE00BD6J9T35.USD","OS","KURA","BK4157","IE00B66KJ199.SGD","AEIS","BK4195","ORR","BK4505","LU0053671581.USD","LU0300736062.USD","BK4139","LU0300736492.USD","FTI","PFS","BK4179","BK4211","IE00B19Z4B17.USD","LU0054578231.USD","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2530883352","title":"Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2530883352","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530883352?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:01","pubTimestamp":1745838060,"startTime":"0","endTime":"0","summary":"Lynozyfic will provide a new option withconvenient dosing and administration to patients who face cycles of relapse and remission. TARRYTOWN, N.Y., April 28, 2025  -- Regeneron Pharmaceuticals, Inc.  today announced that the European Commission  has granted conditional marketing approval of Lynozyfic  to treat adults with relapsed and refractory (R/R) multiple myeloma . The indication is specific to those who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy. Lynozyfic is a bispecific antibody designed to bridge B-cell maturation antigen  on MM cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing.Lynozyfic is the first BCMAxCD3 therapy approved that can be dosed every four weeks due to a response-adapted regimen if a very good partial response  or better is achieved following completion of at lea","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lynozyfic-linvoseltamab-approved-european-union-110100851.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EC","LU1917777945.USD","CR","LU2362541513.USD","ORR","LU2023250504.SGD","LU2089984988.USD","BK4588","BK4201","BK4585","LU2362541273.HKD","BK4139","LU2362540622.SGD","LU0058720904.USD","LU0882574055.USD","LU0889565916.HKD","LU2468319806.SGD","LU2106854487.HKD","BK4161","LU0289739699.SGD","LU0053666078.USD","LU1974910355.USD","LU0320765992.SGD","LU0823416689.USD","LU2237438978.USD","REGN","LU0109394709.USD","LU0114720955.EUR"],"gpt_icon":0},{"id":"2530685901","title":"ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2530685901","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530685901?lang=en_us&edition=fundamental","pubTime":"2025-04-26 01:10","pubTimestamp":1745601000,"startTime":"0","endTime":"0","summary":"- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide  was well-tolerated and demonstrated promising anti-tumor activity. - Combination generated complete responses  in 83% of patients with indolent relapsed or refractory B-cell non-Hodgkin lymphoma  comparing favorably to 34% historical CR rate with R2 alone. - Phase 2 portion of trial in patients with previously untreated indolent NHL  is ongoing and has completed enrollment. After a median follow-up of 28 months  the two-year progression-free survival  rate was 69% and two-year overall survival  rate was 84%. Sixteen patients (80%) achieved complete responses and the best overall response rate  was 90%. As previously repo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alx-oncology-announces-encouraging-final-171000715.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SMP","ALX","BK4161","BK4124","BK4097","BK4139","BK4231","CR","ORR","BK4080","OS","PFS","ALXO","BK4195","BK4211"],"gpt_icon":0},{"id":"2530513653","title":"ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2530513653","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530513653?lang=en_us&edition=fundamental","pubTime":"2025-04-25 21:00","pubTimestamp":1745586000,"startTime":"0","endTime":"0","summary":"In ASPEN-03 and ASPEN-04 trials, efficacy data do not support advancing evorpacept in combination with Merck’s anti-PD-1 therapy, KEYTRUDA , into a registrational study. Company remains confident in continuing to pursue evorpacept in multiple clinical trials, based on the different mechanism of evorpacept in combination with anti-cancer antibodies, as evidenced by durable clinical response and consistent safety data in prior clinical trials. In the ASPEN-03 and ASPEN-04 clinical trials, evorpacept was combined with pembrolizumab with or without chemotherapy to investigate a second and distinct mechanism of action. This discrete approach explored the concept that evorpacept may enhance T-cell priming by activating dendritic cells and stimulating the adaptive immune system. The trial outcomes were not sufficiently supportive of advancing evorpacept in combination with pe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alx-oncology-reports-aspen-03-130000813.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0211331839.USD","LU1983299246.USD","IE00B1BXHZ80.USD","BK4516","SG9999014567.USD","LU2089984988.USD","IE000M9KFDE8.USD","LU0203345920.USD","IE0002141913.USD","ALX","LU1037948541.HKD","LU1037948897.HKD","ALXO","LU1093756325.SGD","IE00B2B36J28.USD","SG9999014559.SGD","LU0265550946.USD","LU1116320901.HKD","IE00BN8TJ469.HKD","LU2468319806.SGD","LU0965509283.SGD","LU1941712264.USD","LU1116320737.USD","LU1057294990.SGD","LU1989772840.SGD","BK4231","LU1934455277.USD","MRK","BK4080","PFS","BK4097","LU2106854487.HKD","LU1066051811.HKD","ORR","OS","LU1934455194.USD","SG9999014542.SGD","BK4550","LU2461242641.AUD","IE00BFTCPJ56.SGD","LU0234572021.USD","LU1974910355.USD","LU1069347547.HKD","LU0861579265.USD","LU1291159041.SGD","LU0965508806.USD","SG9999001176.USD","LU1934455863.HKD","LU1917777945.USD","LU1035773651.USD"],"gpt_icon":0},{"id":"2529818619","title":"CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2529818619","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529818619?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:15","pubTimestamp":1745496900,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANSCISCO, Calif, April 24, 2025  -- CERo Therapeutics Holdings, Inc.,   an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that Sarah Cannon Research Institute  at Colorado Blood Cancer Institute  in Denver, Colorado will be a key clinical trial site for the Company’s Phase 1 clinical trial of CER-1236. Partnering with SCRI to advance cancer research, CBCI is the region’s leader in blood cancer care and serves a seven-state region. The trial is focused on patients with acute myeloid leukemia , and patient enrollment is underway with first dosing of the initial cohort of patients expected by June.CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and ad","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cero-therapeutics-holdings-inc-announces-121500646.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CERO","PK","BK4218","BK4161","CR","ORR","BK4181","CEROW","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":117,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{}}}